High-Dose Atorvastatin for Vascular Wall Protection in Thrombectomy Patients

Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorZhongda Hospital

About this trial

This project investigates the impact of statins on cerebral vascular wall damage after mechanical thrombectomy. The investigators will undertake a multi-center, prospective, parallel-controlled, open-label, superiority randomized controlled study based on past research on intense lipid-lowering intervention trials. Patients undergoing post-thrombectomy will be divided into two groups: the test group and the control group. After surgery, the test group will be given a high dose of atorvastatin (80mg/day), followed by a standard dose (20mg/day). The control group will continue to receive the standard dose of atorvastatin (20mg/day). The investigators will compare the high-resolution vascular wall MRI characteristics (vascular wall enhancement, lumen stenosis rate, and so on) within 3-5 days of the operation, as well as the composite incidence of ischemic stroke, transient ischemic attack, intracranial hemorrhage 1 month postoperatively, and the modified Rankin Score at 90 days.

Eligibility criteria

Qualifiers

Clinical diagnosis of acute ischemic stroke;

With anterior circulation acute stroke who meet and receive emergency endovascular treatment;

CTA or DSA confirms anterior circulation intracranial arterial lesions, including MT of intracranial arteries (middle cerebral artery (MCA), internal carotid artery (ICA), basilar artery and/or vertebral artery and P1 segment of posterior cerebral artery (PCA);

Recanalization of blood vessels after operation (mTICI ≥ 2b grade)

Disqualifiers

Placing permanent stents or other implants in the target artery

Can not receive HR-VWI examination of 3T MRI due to claustrophobia or unstable condition

Contraindications to MRI and/or intravenous gadolinium

Trial design

Treatments tested in this trial

  • Atorvastatin 80mg
  • Atorvastatin 20mg

Treatment groups

162 Participants
are divided into 2 treatment groups

Sponsors and collaborators